Correlation Between Dermata Therapeutics and Aclarion

Can any of the company-specific risk be diversified away by investing in both Dermata Therapeutics and Aclarion at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Dermata Therapeutics and Aclarion into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Dermata Therapeutics Warrant and Aclarion, you can compare the effects of market volatilities on Dermata Therapeutics and Aclarion and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dermata Therapeutics with a short position of Aclarion. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dermata Therapeutics and Aclarion.

Diversification Opportunities for Dermata Therapeutics and Aclarion

-0.02

Correlation Coefficient

Dermata Therapeutics  Aclarion

Good diversification

The 3 months correlation between Dermata and Aclarion is -0.02. Overlapping area represents the amount of risk that can be diversified away by holding Dermata Therapeutics Warrant and Aclarion in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aclarion and Dermata Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dermata Therapeutics Warrant are associated (or correlated) with Aclarion. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aclarion has no effect on the direction of Dermata Therapeutics i.e., Dermata Therapeutics and Aclarion go up and down completely randomly.

Pair Corralation between Dermata Therapeutics and Aclarion

Assuming the 90 days horizon Dermata Therapeutics Warrant is expected to generate 19.4 times more return on investment than Aclarion. However, Dermata Therapeutics is 19.4 times more volatile than Aclarion. It trades about 0.18 of its potential returns per unit of risk. Aclarion is currently generating about -0.08 per unit of risk. If you would invest  1.78  in Dermata Therapeutics Warrant on September 12, 2024 and sell it today you would lose (0.86) from holding Dermata Therapeutics Warrant or give up 48.31% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	47.13%
Values	Daily Returns

Dermata Therapeutics Warrant  vs.  Aclarion

Dermata Therapeutics

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Dermata Therapeutics Warrant are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Dermata Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Aclarion

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aclarion has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Aclarion is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Dermata Therapeutics and Aclarion

The main advantage of trading using opposite Dermata Therapeutics and Aclarion positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dermata Therapeutics position performs unexpectedly, Aclarion can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aclarion will offset losses from the drop in Aclarion's long position.

The idea behind Dermata Therapeutics Warrant and Aclarion pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.